Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$38 Mln
Revenue (TTM)
$0 Mln
Net Profit (TTM)
$0 Mln
ROE
-0.6 %
ROCE
-- %
P/E Ratio
--
P/B Ratio
1
Industry P/E
27.34
EV/EBITDA
42.9
Div. Yield
0 %
Debt to Equity
0
Book Value
$--
EPS
$-1.2
Face value
--
Shares outstanding
16,050,320
CFO
$-168.67 Mln
EBITDA
$-233.07 Mln
Net Profit
$-223.89 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Veru (VERU)
| 7.5 | -2.1 | 3.1 | -53.6 | -47.6 | -56.6 | -19.9 |
|
BSE Sensex
| -9.4 | -8.1 | -9.3 | 3.4 | 9.8 | 9.0 | 12.0 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Veru (VERU)
| -67.1 | -9.6 | -86.4 | -10.4 | -31.9 | 158.2 | 139.3 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Veru (VERU)
|
2.3 | 38.4 | 0.3 | -19.1 | -4,112.8 | -72.9 | -- | 1.0 |
| 1.2 | 161.9 | 300.8 | -9.5 | 3.9 | -16.8 | -- | 2.5 | |
| 87.5 | 71,209.5 | 20,382.0 | 2,132.0 | 15.4 | 1603 | 33.8 | 1,305.5 | |
| 19.9 | 923.1 | 2,167.9 | -38.2 | 2.9 | -2.5 | 179.6 | 0.6 | |
| 88.1 | 2,933.8 | 1,488.5 | 168.4 | 16.3 | 20.7 | 17.5 | 3.3 | |
| 7.2 | 476.8 | 1,485.2 | 160.2 | 14.2 | 22 | 4.5 | 0.4 | |
| 1.3 | 803.3 | 423.0 | -9.3 | 3.8 | -1.1 | -- | 0.9 | |
| 146.7 | 352,594.1 | 85,259.0 | 16,466.0 | 18.6 | 31.1 | 22.3 | 6.7 | |
| 0.3 | 25.5 | 4.8 | 0.0 | -7.9 | -151.6 | -- | 0.0 | |
| 3.6 | 623.2 | 4,181.0 | -78.7 | -2.3 | -2.6 | -- | 0.9 |
Veru Inc., a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and viral-induced acute respiratory distress syndrome (ARDS) in Florida and internationally. It provides FC2... female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections. The company develops enobosarm, a selective androgen receptor modulator for treatment of augment fat loss and to prevent muscle loss in sarcopenic obese and overweight elderly patients; Enobosarm, an oral selective androgen receptor modulator for the treatment of AR+ ER+ HER2- metastatic breast cancer; and sabizabulin, a microtubule disruptor for the treatment of hospitalized patients with viral lung infection at high risk for viral induced ARDS and death. The company was formerly known as The Female Health Company and changed its name to Veru Inc. in July 2017. Veru Inc. was incorporated in 1971 and is headquartered in Miami, Florida. Read more
Chairman, President & CEO
Dr. Mitchell S. Steiner F.A.C.S., M.D.
Chairman, President & CEO
Dr. Mitchell S. Steiner F.A.C.S., M.D.
Headquarters
Miami, FL
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Veru Inc (VERU) is $2.30 (NASDAQ) as of 18-Mar-2026 16:27 EDT. Veru Inc (VERU) has given a return of -47.62% in the last 3 years.
Since, TTM earnings of Veru Inc (VERU) is negative, P/E ratio is not available.
The P/B ratio of Veru Inc (VERU) is 1.03 times as on 13-Mar-2026, a 89 discount to its peers’ median range of 9.52 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
-2.51
|
3.11
|
|
2024
|
-0.26
|
0.31
|
|
2023
|
-0.06
|
0.29
|
|
2022
|
-1.10
|
1.11
|
|
2021
|
9.23
|
0.45
|
The 52-week high and low of Veru Inc (VERU) are Rs 7.40 and Rs 2.10 as of 19-Mar-2026.
Veru Inc (VERU) has a market capitalisation of $ 38 Mln as on 13-Mar-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Veru Inc (VERU), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
$-0.11
(
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.